Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

161. Tucatinib (Tukysa) - To treat advanced unresectable or metastatic HER2-positive breast cancer

Tucatinib (Tukysa) - To treat advanced unresectable or metastatic HER2-positive breast cancer Drug Approval Package: TUKYSA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TUKYSA Company: Seattle Genetics, Inc. Application Number: 213411 Approval Date: 04/17/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2020 FDA - Drug Approval Package

162. Sacituzumab govitecan-hziy (Trodelvy) - To treat adult patients with metastatic triple-negative breast cancer

Sacituzumab govitecan-hziy (Trodelvy) - To treat adult patients with metastatic triple-negative breast cancer Drug Approval Package: TRODELVY U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TRODELVY Company: Immunomedics, Inc Application Number: 761115 Approval Date: 04/22/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

2020 FDA - Drug Approval Package

163. Management of essential cancer surgery for adults during the coronavirus pandemic

pandemic and/or the intervention is non-priority based on the magnitude of benefit (e.g. no survival gain with no change nor reduced QoL). They also include guidance around treatment and prioritisation for: Breast cancer in the COVID-19 era Gastrointestinal cancers: Colorectal cancer (CRC) in the COVID-19 era Gastrointestinal cancers: Gastro-oesophageal tumours in the COVID-19 era Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era Gastrointestinal cancers: Pancreatic cancer (...) ). The Annals of Thoracic Surgery America A consensus statement around triage of operations for thoracic malignancies. Ramakrishna et al (2020) Inpatient and America and Canada 11 outpatient case prioritization for patients with neuro -oncologic disease amid the COVID -19 pandemic: general guidance for neuro -oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro -Oncology. Journal of Neuro- Oncology A framework for institutions and governments to help adjudicate treatment allocations

2020 Covid-19 Ad hoc papers

164. Larotrectinib for treating NTRK fusion-positive solid tumours

live after their disease gets worse. Collecting more data would help to address some of the uncertainties in the clinical evidence. Larotrectinib has the potential to be a cost-effective use of NHS resources at its current price so it is recommended through the Cancer Drugs Fund while these data are collected. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice (...) is needed characterisation is needed 3.2 NTRK gene fusions occur rarely (less than 1%) in common tumours such as lung, colorectal and breast cancers. Some rare tumour types have more than 90% NTRK fusion prevalence (for example, mammary analogue secretory carcinoma and infantile fibrosarcoma). There are many tumour types with known NTRK gene fusions and all solid tumour types are included in larotrectinib's marketing authorisation. NTRK fusions can involve portions of the NTRK1, NTRK2 and NTRK3 genes

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

165. Archimedes for biopsy of suspected lung cancer

navigation systems. Archimedes for biopsy of suspected lung cancer (MIB211) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 10Current care pathway Current care pathway People with known or suspected lung cancer should be offered a contrast-enhanced chest CT scan to diagnosis and stage the disease. They should also be offered endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for biopsy (...) of paratracheal and peri-bronchial intra- parenchymal lung lesions. When taking samples, the healthcare professional should ensure they are adequate (without unacceptable risk to the person) to permit pathological diagnosis, including tumour subtyping and assessment of predictive markers. The following publications have been identified as relevant to this care pathway: • NICE's guideline on lung cancer: diagnosis and management • NICE's quality standard on lung cancer in adults • NICE's interventional

2020 National Institute for Health and Clinical Excellence - Advice

166. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer

nodes after neoadjuvant taxane-based and HER2-targeted therapy. It is recommended only if the company provides trastuzumab emtansine according to the commercial arrangement. Why the committee made these recommendations Why the committee made these recommendations Neoadjuvant therapy aims to reduce the size of the tumour before surgery. It sometimes shrinks completely, but people may still have cancer remaining when they have their surgery (residual invasive disease). The cancer may have spread (...) to eradicate or reduce tumour size before surgery. NICE recommends pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer, with trastuzumab and chemotherapy, for locally advanced, inflammatory or early breast cancer at high risk of recurrence. The patient expert explained that when residual disease is found during surgery this is a disappointing outcome, and preventing the cancer returning is very important to patients. After surgery, adjuvant treatment is used to reduce the risk

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

167. Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer

Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer Variation in the Association Between Antineoplastic Therapies and Venous Thromboembolism in Patients With Active Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National (...) : Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Haemost Actions . 2020 May;120(5):847-856. doi: 10.1055/s-0040-1709527. Epub 2020 May 5. Variation in the Association Between Antineoplastic Therapies and Venous Thromboembolism in Patients With Active Cancer , , , , , , , , , Affiliations Expand Affiliations 1 Vascular and Emergency Medicine and Stroke Unit, University of Perugia, Perugia, Perugia, Italy. 2 Division of Cardiology

2020 EvidenceUpdates

168. Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Kyushu Cancer Center, Fukuoka, Japan. 11 Department of General Thoracic Surgery, Breast and Endocrinological Surgery, Okayama University, Okayama, Japan. 12 Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan. 13 Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. 14 Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 15 Department (...) Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History

2020 EvidenceUpdates

169. Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT Full Text available with Trip Pro

Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This trial found no evidence of any difference between talc poudrage at thorocoscopy and bedside chest drain and talc slurry for the management of malignant pleural effusion. {{author}} {{($index , , , , & . Rahul Bhatnagar 1 , Ramon Luengo-Fernandez 2 , Brennan C Kahan 3 , Najib M Rahman 4 , Robert F Miller 5 , Nick A Maskell 1

2020 NIHR HTA programme

170. The EAU – EANM – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer

. Association of male circumcision with risk of prostate cancer: a meta-analysis. Prostate Cancer Prostatic Dis, 2015. 18: 352. 73. Rider, J.R., et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol, 2016. 70: 974. 74. Brierley, J.D., et al., TNM classification of malignant tumors. UICC International Union Against Cancer. 8th edn. 2017. 75. Cooperberg, M.R., et al. The University of California, San Francisco Cancer of the Prostate Risk (...) of atypical small acinar proliferation. Can J Urol, 2017. 24: 8714. 219. Epstein, J.I., et al. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol, 2006. 175: 820. 220. Merrimen, J.L., et al. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol, 2009. 182: 485. 221. Kronz, J.D., et al. High-grade prostatic intraepithelial neoplasia

2020 European Association of Nuclear Medicine

171. Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations. (Abstract)

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population.In this open-label, phase 2 study, we administered tepotinib (at a dose of 500 mg) once daily in patients with advanced (...) of the previous therapy received for advanced or metastatic disease. Adverse events of grade 3 or higher that were considered by investigators to be related to tepotinib therapy were reported in 28% of the patients, including peripheral edema in 7%. Adverse events led to permanent discontinuation of tepotinib in 11% of the patients. A molecular response, as measured in circulating free DNA, was observed in 67% of the patients with matched liquid-biopsy samples at baseline and during treatment.Among patients

2020 NEJM

172. Olaparib for Metastatic Castration-Resistant Prostate Cancer. (Abstract)

Olaparib for Metastatic Castration-Resistant Prostate Cancer. Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with prostate and other cancers.We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease (...) with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone. (Funded by AstraZeneca and Merck Sharp & Dohme; PROfound ClinicalTrials.gov number, NCT02987543.).Copyright © 2020 Massachusetts Medical

2020 NEJM

173. WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition. (Abstract)

and murine models.In this study involving patients with disorders resulting in a predisposition to the development of multiple malignant neoplasms without PTEN germline mutations, we confirmed the function of WWP1 as a cancer-susceptibility gene through direct aberrant regulation of the PTEN-PI3K signaling axis. (Funded by the National Institutes of Health and others.).Copyright © 2020 Massachusetts Medical Society. (...) WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition. Patients with PTEN hamartoma tumor syndrome (PHTS) have germline mutations in the tumor-suppressor gene encoding phosphatase and tensin homologue (PTEN). Such mutations have been associated with a hereditary predisposition to multiple types of cancer, including the Cowden syndrome. However, a majority of patients who have PHTS-related phenotypes have tested negative for PTEN mutations. In a previous study, we found that the E3

2020 NEJM

174. Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. Full Text available with Trip Pro

Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. To evaluate the long term risks of invasive breast cancer and death from breast cancer after ductal carcinoma in situ (DCIS) diagnosed through breast screening.Population based observational cohort study.Data from the NHS Breast Screening Programme and the National Cancer Registration and Analysis (...) treatment (mastectomy, radiotherapy for women who had breast conserving surgery, and endocrine treatment in oestrogen receptor positive disease) and those with larger final surgical margins had lower rates of invasive breast cancer.To date, women with DCIS detected by screening have, on average, experienced higher long term risks of invasive breast cancer and death from breast cancer than women in the general population during a period of at least two decades after their diagnosis. More intensive

2020 BMJ

175. Long-Term Colorectal Cancer Incidence and Mortality After a Single Negative Screening Colonoscopy. (Abstract)

Long-Term Colorectal Cancer Incidence and Mortality After a Single Negative Screening Colonoscopy. Current guidelines recommend a 10-year interval between screening colonoscopies, but evidence is limited.To assess the long-term risk for colorectal cancer (CRC) and death from CRC after a high- and low-quality single negative screening colonoscopy.Observational study.Polish Colonoscopy Screening Program.Average-risk individuals aged 50 to 66 years who had a single negative colonoscopy (...) (no neoplastic findings).Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) of CRC after high- and low-quality single negative screening colonoscopy. High-quality colonoscopy included a complete examination, with adequate bowel preparation, performed by endoscopists with an adenoma detection rate of 20% or greater.Among 165 887 individuals followed for up to 17.4 years, CRC incidence (0.28 [95% CI, 0.25 to 0.30]) and mortality (0.19 [CI, 0.16 to 0.21]) were 72% and 81% lower

2020 Annals of Internal Medicine

176. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. (Abstract)

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Atezolizumab can induce sustained responses in metastatic urothelial carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or without platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in first-line metastatic urothelial carcinoma.In this multicentre, phase 3, randomised trial (...) , untreated patients aged 18 years or older with locally advanced or metastatic urothelial carcinoma, from 221 sites in 35 countries, were randomly assigned to receive atezolizumab plus platinum-based chemotherapy (group A), atezolizumab monotherapy (group B), or placebo plus platinum-based chemotherapy (group C). Patients received 21-day cycles of gemcitabine (1000 mg/m2 body surface area, administered intravenously on days 1 and 8 of each cycle), plus either carboplatin (area under the curve of 4·5 mg

2020 Lancet

177. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. (Abstract)

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.In a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib until (...) unacceptable toxic effects occurred or there was a loss of clinical benefit. The coprimary end points were overall survival and progression-free survival in the intention-to-treat population, as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).The intention-to-treat population included 336 patients in the atezolizumab-bevacizumab group and 165 patients in the sorafenib group. At the time of the primary analysis (August 29, 2019

2020 NEJM

178. Clinical Practice Guidelines – Thyroid cancer

with different risks of malignancy [11]. Most malignant thyroid tumours can be identi?ed cytologically. Notable exceptions are FTCs and the newly de?ned ‘non-invasive follicular thyroid neoplasm with papillary-like nuclear features’ (NIFTP), which are usually classi?ed as indeterminate in the vari- ous thyroid cytology reporting schemes [12]. FNA-based diagno- sis of poorly differentiated carcinoma is also challenging unless there is obviously increased mitotic activity and/or necrosis. FNA diagnosis can (...) Including papillary, follicular, Hu ¨rthle cell and poorly differentiated carcinomas. ATC, anaplastic thyroid cancer; pN, pathological node; pT, pathological tumour; TNM, tumour, node, metastasis; UICC, Union for International Cancer Control. Adapted from [23] with permission from John Wiley & Sons, Inc. Annals of Oncology Special article Volume 30 | Issue 12 | 2019 doi:10.1093/annonc/mdz400 | 1859Table 3. Risk strati?cation system for the prediction of persistent or recurrent disease in DTC patients

2020 European Society for Medical Oncology

179. Cancer Patient Management During COVID-19 Pandemic

that older people are more vulnerable, with underlying health conditions such as chronic respiratory, cardio-vascular or chronic kidney disease, diabetes, active cancer and more generally severe chronic diseases. Therefore, during the COVID-19 pandemic, the Benefit/Risk ratio of cancer treatment may need to be reconsidered in certain patients. Two groups of patients have been identified: “patients off therapy” (A) who have completed a treatment or have disease under control (off therapy); and patients (...) . Clinical staff responsible for the checkpoint area should be trained and wear PPE. Individuals who meet criteria for highly communicable diseases requiring isolation, such as novel COVID-19 or other emerging infections, must be placed in a private exam room as soon as possible, as per the infectious control guidance found on the WHO and CDC websites. They should be tested and transferred to COVID-19 dedicated areas. In cancer patients, categories at risk include: Patients receiving chemotherapy, or who

2020 European Society for Medical Oncology

180. eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations

cancer (NSCLC) who have not progressed following chemoradiotherapy whose tumours express programmed death-ligand 1 (PD-L1) on ≥1% of tumour cells, although the latter was a post hoc subgroup analysis. The recommendation is based on the phase III PACIFIC trial, in which the PD-L1 inhibitor durvalumab, commenced 1–42 days post chemoradiotherapy, improved both progression-free survival [PFS; median PFS 16.8 versus 5.6 months; hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.42–0.65, P <0.0001 (...) durvalumab, 1 to 42 days after the end of chemoradiotherapy has demonstrated a survival benefit in unresectable stage III NSCLC and is recommended in patients whose tumours express PD-L1 on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemoradiotherapy (as per the EMA approved indication) [I, A; European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) v1.1 score: 4] in the intention to treat population across all PD-L1 categories]. ESMO

2020 European Society for Medical Oncology